Bortezomib-Induced Multiple Chalazia: A Case Report - Case Reports in Clinical Medicine

CRCM > Vol.4 No.1, January 2015

Bortezomib-Induced Multiple Chalazia: A Case Report (Short Report)

HTML XML

Download as PDF (Size: 2611KB) PP. 32-35

DOI: 10.4236/crcm.2015.41008 3,280 Downloads 4,222 Views Citations

Author(s)

Rania Mohamed¹, Horace Massa², Claude Schwarz², Nicole Grandjean-Hallez³, Kaveh Samii¹

Affiliation(s)

¹Hematology Department, University of Geneva Hospitals, Geneva, Switzerland.
²Ophtalmology Department, University of Geneva Hospitals, Geneva, Switzerland.
³Oncology Department, University of Geneva Hospitals, Geneva, Switzerland.

ABSTRACT

Bortezomib is a novel agent for the treatment of patients with multiple myeloma. Several cutaneous lesions have been associated with its use and chalazia have been reported in a few cases with a delayed appearance ranging from 1 to 6 months. We describe the case of a 59-year-old man with multiple myeloma IgG kappa, ISS2, who developed a chalazion induced by bortezomib. Following the failure of conservative treatment, a biopsy was performed to exclude extramedullary plasmocytoma. Bortezomib was discontinued due to the persistence of lesions and a therapeutic approach combining systemic antibiotics with incision and curettage was adopted. An active inflammatory lesion developed after 1 month, similar to that observed under bortezomib therapy. Symptoms resolved only 5 months later and the patient remained free of any ocular manifestation. Physicians should be aware that chalazia may be resistant to conventional treatment and lead to local complications, such as cellulitis.

KEYWORDS

Bortezomib, Chalazion, Meibomian Gland

Share and Cite:

Mohamed, R. , Massa, H. , Schwarz, C. , Grandjean-Hallez, N. and Samii, K. (2015) Bortezomib-Induced Multiple Chalazia: A Case Report. Case Reports in Clinical Medicine, 4, 32-35. doi: 10.4236/crcm.2015.41008.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies